Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359376 | 0.80 | BACE1 (0.46) | CNR2HTR2AHTR2CSLC6A4RORC | |
| SCHEMBL19359467 | 0.76 | LMNA (0.52) | GAALMNATP53 | |
| SCHEMBL19359166 | 0.71 | MPO (0.46) | CNR2LMNATP53CNR1 | |
| SCHEMBL13911246 | 0.67 | GAA (0.67) | CNR2HTR2AHTR2CSLC6A4GAA | |
| SCHEMBL15677245 | 0.67 | RORC (0.58) | CNR2HTR2AHTR2CSLC6A4RORC | |
| SCHEMBL13686805 | 0.67 | CNR2 (0.47) | CNR2HTR2AHTR2CSLC6A4TAS2R14 | |
| SCHEMBL19359266 | 0.66 | POLB (0.42) | LMNATP53 | |
| SCHEMBL984791 | 0.66 | TAS2R14 (0.71) | CNR2TAS2R14 | |
| SCHEMBL5010583 | 0.66 | HTR2A (0.81) | CNR2HTR2AHTR2CSLC6A4GAA | |
| SCHEMBL15677741 | 0.65 | RXFP1 (0.63) | CNR2HTR2AHTR2CSLC6A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | CNR2 2634/4885HTR2A 4364/4885HTR2C 4237/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | CNR2 2634/4885HTR2A 4364/4885HTR2C 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.